Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice.

Wan W, Lionakis MS, Liu Q, Roffê E, Murphy PM.

Cardiovasc Res. 2013 Mar 1;97(3):580-8. doi: 10.1093/cvr/cvs349. Epub 2012 Nov 24.

2.

TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.

Wu C, He S, Peng Y, Kushwaha KK, Lin J, Dong J, Wang B, Lin J, Shan S, Liu J, Huang K, Li D.

J Mol Cell Cardiol. 2014 Nov;76:33-45. doi: 10.1016/j.yjmcc.2014.07.003. Epub 2014 Aug 10.

PMID:
25117469
3.

Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice.

Wan W, Lim JK, Lionakis MS, Rivollier A, McDermott DH, Kelsall BL, Farber JM, Murphy PM.

Circ Res. 2011 Aug 5;109(4):374-81. doi: 10.1161/CIRCRESAHA.111.242578. Epub 2011 Jun 16.

4.

Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development.

Guo J, de Waard V, Van Eck M, Hildebrand RB, van Wanrooij EJ, Kuiper J, Maeda N, Benson GM, Groot PH, Van Berkel TJ.

Arterioscler Thromb Vasc Biol. 2005 May;25(5):1014-9. Epub 2005 Mar 17.

5.

Deficiency in lymphotoxin β receptor protects from atherosclerosis in apoE-deficient mice.

Grandoch M, Feldmann K, Göthert JR, Dick LS, Homann S, Klatt C, Bayer JK, Waldheim JN, Rabausch B, Nagy N, Oberhuber A, Deenen R, Köhrer K, Lehr S, Homey B, Pfeffer K, Fischer JW.

Circ Res. 2015 Apr 10;116(8):e57-68. doi: 10.1161/CIRCRESAHA.116.305723. Epub 2015 Mar 4.

6.

Bone marrow-specific knock-in of a non-activatable Ikkα kinase mutant influences haematopoiesis but not atherosclerosis in Apoe-deficient mice.

Tilstam PV, Gijbels MJ, Habbeddine M, Cudejko C, Asare Y, Theelen W, Zhou B, Döring Y, Drechsler M, Pawig L, Simsekyilmaz S, Koenen RR, de Winther MP, Lawrence T, Bernhagen J, Zernecke A, Weber C, Noels H.

PLoS One. 2014 Feb 3;9(2):e87452. doi: 10.1371/journal.pone.0087452. eCollection 2014.

7.

Atypical chemokine receptor 1 deficiency reduces atherogenesis in ApoE-knockout mice.

Wan W, Liu Q, Lionakis MS, Marino AP, Anderson SA, Swamydas M, Murphy PM.

Cardiovasc Res. 2015 Jun 1;106(3):478-87. doi: 10.1093/cvr/cvv124. Epub 2015 Apr 8.

8.

Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo.

Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F.

Circulation. 2005 Aug 9;112(6):870-8. Epub 2005 Aug 1.

9.

Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.

Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3781-6. Epub 2006 Mar 1.

10.

MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice.

Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, Lu H, Fan D.

Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):759-67. doi: 10.1161/ATVBAHA.113.302701. Epub 2014 Feb 6.

11.

Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice.

Li MW, Mian MO, Barhoumi T, Rehman A, Mann K, Paradis P, Schiffrin EL.

Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2306-15. doi: 10.1161/ATVBAHA.113.302028. Epub 2013 Jul 25.

12.

Reduced Atherosclerosis in apoE-inhibitory FcγRIIb-Deficient Mice Is Associated With Increased Anti-Inflammatory Responses by T Cells and Macrophages.

Ng HP, Zhu X, Harmon EY, Lennartz MR, Nagarajan S.

Arterioscler Thromb Vasc Biol. 2015 May;35(5):1101-12. doi: 10.1161/ATVBAHA.115.305290. Epub 2015 Mar 19.

13.

Chemokine receptor 7 knockout attenuates atherosclerotic plaque development.

Luchtefeld M, Grothusen C, Gagalick A, Jagavelu K, Schuett H, Tietge UJ, Pabst O, Grote K, Drexler H, Förster R, Schieffer B.

Circulation. 2010 Oct 19;122(16):1621-8. doi: 10.1161/CIRCULATIONAHA.110.956730. Epub 2010 Oct 4.

14.

Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression.

Morris-Rosenfeld S, Blessing E, Preusch MR, Albrecht C, Bierhaus A, Andrassy M, Nawroth PP, Rosenfeld ME, Katus HA, Bea F.

Eur J Clin Invest. 2011 Nov;41(11):1164-71. doi: 10.1111/j.1365-2362.2011.02514.x. Epub 2011 Mar 21.

PMID:
21418204
16.

Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.

Damås JK, Smith C, Øie E, Fevang B, Halvorsen B, Waehre T, Boullier A, Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, Taskén K, Frøland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P.

Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):614-20. Epub 2006 Dec 14.

17.

Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/- mice.

Kanno S, Nishio H, Tanaka T, Motomura Y, Murata K, Ihara K, Onimaru M, Yamasaki S, Kono H, Sueishi K, Hara T.

J Immunol. 2015 Jan 15;194(2):773-80. doi: 10.4049/jimmunol.1302841. Epub 2014 Dec 8.

18.

Nrf2 in bone marrow-derived cells positively contributes to the advanced stage of atherosclerotic plaque formation.

Harada N, Ito K, Hosoya T, Mimura J, Maruyama A, Noguchi N, Yagami K, Morito N, Takahashi S, Maher JM, Yamamoto M, Itoh K.

Free Radic Biol Med. 2012 Dec 15;53(12):2256-62. doi: 10.1016/j.freeradbiomed.2012.10.001. Epub 2012 Oct 7.

PMID:
23051009
19.
20.

Accelerated atherosclerosis in Apoe-/- mice heterozygous for the insulin receptor and the insulin receptor substrate-1.

Galkina EV, Butcher M, Keller SR, Goff M, Bruce A, Pei H, Sarembock IJ, Sanders JM, Nagelin MH, Srinivasan S, Kulkarni RN, Hedrick CC, Lattanzio FA, Dobrian AD, Nadler JL, Ley K.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):247-56. doi: 10.1161/ATVBAHA.111.240358. Epub 2011 Dec 22.

Supplemental Content

Support Center